Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/FtwtaTAF_N4   Nirsevimab is a long-acting anti-RSV monoclonal antibody that can prevent this often serious childhood respiratory illness in 75% of healthy infants.  Pediatric investigators at Northwestern and the Lurie Children’s Hospital in Chicago now report the results of their phase 3 clinical trial in the New England Journal of Medicine.    A total of 1490 term infants underwent 2:1 randomization to receive nirsevimab or a control injection.  RSV infections that required significant medical care occurred in only 1.2% of the treated group vs 5% of controls, a 76% reduction.  Hospitalization for RSV therapy was necessary for only 0.6% of the treated group vs 1.6% of the controls representing a 62% reduction.  Nirsevimab injection was not associated with any increased adverse effects.   The best news is that a single injection of this immunizing medication can protect an infant for the entire RSV season.   https://www.nejm.org/doi/10.1056/NEJMoa2110275   #nirsevimab #rsv #hospit